Gene: FOXRED2

80020
ERFAD
FAD dependent oxidoreductase domain containing 2
protein-coding
22q12.3
Ensembl:ENSG00000100350 MIM:613777 Vega:OTTHUMG00000044614 UniprotKB:Q8IWF2
NC_000022.11
PubMed
0   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.659e-1 (AD)  2.808e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SLC23A20.894
ASTN10.885
SIRPA0.878
TOM1L20.876
ABR0.874
CAMK2G0.869
KIAA03190.868
MEGF80.867
PTPRS0.867
GNAO10.865

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.57
OR4F29-0.51
TFPI2-0.494
CD48-0.488
SPINK8-0.444
CLEC2B-0.439
CCL5-0.437
CLEC6A-0.436
CCR2-0.434
PLEKHA4-0.433

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXRED2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXRED2 mRNA"27188386
C006632arsenic trioxidearsenic trioxide results in increased expression of FOXRED2 mRNA15761015
C044887beta-methylcholinebeta-methylcholine affects the expression of FOXRED2 mRNA21179406
C006780bisphenol Abisphenol A results in increased expression of FOXRED2 mRNA29275510
C006780bisphenol Abisphenol A results in decreased expression of FOXRED2 mRNA25181051
D003300Copper[NSC 689534 binds to Copper] which results in decreased expression of FOXRED2 mRNA20971185
D019327Copper SulfateCopper Sulfate results in decreased expression of FOXRED2 mRNA19549813
D003375Coumestrol[Coumestrol co-treated with resveratrol] results in increased expression of FOXRED2 mRNA19167446
D016572CyclosporineCyclosporine results in decreased expression of FOXRED2 mRNA25562108
D003907DexamethasoneDexamethasone results in increased expression of FOXRED2 mRNA22733784
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in increased expression of FOXRED2 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of FOXRED2 mRNA27594783
C000944dicrotophosdicrotophos results in increased expression of FOXRED2 mRNA28302478
D004041Dietary FatsDietary Fats results in increased expression of FOXRED2 mRNA25016146
C118739entinostatentinostat results in increased expression of FOXRED2 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXRED2 mRNA"27188386
D005620Freund's AdjuvantFreund's Adjuvant results in increased expression of FOXRED2 mRNA20846436
C069837fullerene C60fullerene C60 results in decreased expression of FOXRED2 mRNA19167457
D007213IndomethacinIndomethacin results in decreased expression of FOXRED2 mRNA28201806
C544151jinfukang[Cisplatin co-treated with jinfukang] results in increased expression of FOXRED2 mRNA27392435
C544151jinfukangjinfukang results in increased expression of FOXRED2 mRNA27392435
D007854LeadLead results in decreased expression of FOXRED2 mRNA19921347
D008727MethotrexateMethotrexate results in decreased expression of FOXRED2 mRNA24449571
C028007nickel monoxidenickel monoxide results in decreased expression of FOXRED2 mRNA19167457
C558013NSC 689534[NSC 689534 binds to Copper] which results in decreased expression of FOXRED2 mRNA20971185
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in increased expression of FOXRED2 mRNA19710929
C059514resveratrol[Coumestrol co-treated with resveratrol] results in increased expression of FOXRED2 mRNA19167446
C017947sodium arsenitesodium arsenite affects the expression of FOXRED2 mRNA29319823
D018038Sodium SeleniteSodium Selenite results in decreased expression of FOXRED2 mRNA18175754
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of FOXRED2 mRNA26377647
D014212TretinoinTretinoin results in decreased expression of FOXRED2 mRNA23724009
C015559trimellitic anhydridetrimellitic anhydride results in decreased expression of FOXRED2 mRNA19042947
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of FOXRED2 mRNA"26179874
D014635Valproic AcidValproic Acid results in increased methylation of FOXRED2 gene29154799
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of FOXRED2 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI19706418  21359175  
GO:0016491oxidoreductase activity-IEA-  
GO:0050660flavin adenine dinucleotide binding-IDA19706418  
GO ID GO Term Qualifier Evidence PubMed
GO:0030433ubiquitin-dependent ERAD pathway-IBA21873635  
GO:0030433ubiquitin-dependent ERAD pathway-IMP19706418  
GO:0055114oxidation-reduction process-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005788endoplasmic reticulum lumen-IBA21873635  
GO:0005788endoplasmic reticulum lumen-IDA19706418  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
27859136KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer. (2017 Feb 15)Nagy AInt J Cancer